An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Public ClinicalTrials.gov record NCT01578785. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate 20mg/0.5ml New Formulation Administered Daily by Subcutaneous Injection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will investigate the efficacy, safety and tolerability of a new formulation of glatiramer acetate administered at 20 mg/0.5 ml daily versus placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
Study identification
- NCT ID
- NCT01578785
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 178 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2012 (Type not available)
- Primary completion
- Oct 2012 (Actual)
- Completion
- Nov 2012 (Actual)
- Last update posted
- Apr 2, 2014
2012
United States locations
- U.S. sites
- 25
- U.S. states
- 9
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 10192 | Cullman | Alabama | — | — |
| Teva Investigational Site 10204 | Fresno | California | — | — |
| Teva Investigational Site 10201 | La Jolla | California | — | — |
| Teva Investigational Site 10196 | Centennial | Colorado | — | — |
| Teva Investigational Site 10184 | Miami | Florida | — | — |
| Teva Investigational Site 10180 | Sarasota | Florida | — | — |
| Teva Investigational Site 10197 | Sarasota | Florida | — | — |
| Teva Investigational Site 10190 | Tampa | Florida | — | — |
| Teva Investigational Site 10207 | Tampa | Florida | — | — |
| Teva Investigational Site 10199 | Vero Beach | Florida | — | — |
| Teva Investigational Site 10181 | Chicago | Illinois | — | — |
| Teva Investigational Site 10202 | Northbrook | Illinois | — | — |
| Teva Investigational Site 10188 | Patchogue | New York | — | — |
| Teva Investigational Site 10198 | Charlotte | North Carolina | — | — |
| Teva Investigational Site 10203 | Hickory | North Carolina | — | — |
| Teva Investigational Site 10209 | Hickory | North Carolina | — | — |
| Teva Investigational Site 10212 | Raleigh | North Carolina | — | — |
| Teva Investigational Site 10213 | Winston-Salem | North Carolina | — | — |
| Teva Investigational Site 10215 | Winston-Salem | North Carolina | — | — |
| Teva Investigational Site 10194 | Akron | Ohio | — | — |
| Teva Investigational Site 10191 | Dayton | Ohio | — | — |
| Teva Investigational Site 10200 | Uniontown | Ohio | — | — |
| Teva Investigational Site 10206 | Cordova | Tennessee | — | — |
| Teva Investigational Site 10214 | Cordova | Tennessee | — | — |
| Teva Investigational Site 10186 | Nashville | Tennessee | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 144 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01578785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2014 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01578785 live on ClinicalTrials.gov.